Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly
Hims & Hers Health stock rose sharply after the company announced a partnership with Eli Lilly to sell the pharmaceutical giant's obesity medications directly through its telehealth platform. The deal gives Hims & Hers exclusive access to Lilly's branded weight-loss drugs, allowing direct-to-consumer sales and expanding the company's reach beyond its existing offerings. This move addresses a key need for the telehealth company to diversify its revenue streams amid competitive pressures in the digital health market.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Hims & Hers Health stock surged following the announcement of a partnership with Eli Lilly to sell weight-loss drugs.
- ✓ Eli Lilly will sell its obesity drugs directly through the Hims & Hers site.
- ✓ The partnership expands access to FDA-approved Lilly medicines through the Hims & Hers platform.
- ✓ Hims & Hers will offer branded weight-loss drugs from Eli Lilly.
What changed
Hims & Hers will now sell Eli Lilly's branded weight-loss drugs exclusively through its direct-to-consumer platform, expanding beyond its previous focus on generic medications and men's health products.
Live updates
-
Hims & Hers Surges On Surprise Deal With Eli Lilly for Weight-Loss Drugs
Hims & Hers Health stock rose sharply after the company announced a partnership with Eli Lilly to sell the pharmaceutical giant's obesity medications directly through its telehealth platform. The deal gives Hims & Hers exclusive access to Lilly's branded weight-loss drugs, allowing direct-to-consumer sales and expanding the company's reach beyond its existing offerings. This move addresses a key need for the telehealth company to diversify its revenue streams amid competitive pressures in the digital health market.
Why it matters
The partnership represents a strategic expansion for Hims & Hers, which has faced challenges in maintaining growth momentum in the telehealth sector. By integrating Lilly's FDA-approved obesity medications into its existing digital platform, the company positions itself to capture a larger share of the rapidly growing weight-loss drug market. This collaboration also reflects a broader trend of digital health companies partnering with pharmaceutical manufacturers to deliver prescription treatments directly to consumers.
What is confirmed
- Hims & Hers Health stock surged following the announcement of a partnership with Eli Lilly to sell weight-loss drugs.
- Eli Lilly will sell its obesity drugs directly through the Hims & Hers site.
- The partnership expands access to FDA-approved Lilly medicines through the Hims & Hers platform.
- Hims & Hers will offer branded weight-loss drugs from Eli Lilly.
What to watch next
- Regulatory approval timelines for Lilly's weight-loss drugs on the Hims & Hers platform
- Revenue contribution from the Lilly partnership to Hims & Hers financial results
- Expansion of the partnership to include additional Lilly medications beyond obesity drugs
confidence 90%Sources used for this update (13)
- contents.premium.naver.com — [잠옷입고 경제공부] 세계 무역지도를 바꿀 사건!
- Investor's Business Daily — Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly
- Reuters — Lilly to sell obesity drugs directly on Hims & Hers site
- PR Newswire — Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
- Bloomberg.com — Lilly, Hims Join Forces to Reach More Weight-Loss Drug Patients
- FirstWord Pharma — Lilly turns to Hims & Hers to boost access to obesity drugs in US
- Fierce Healthcare — Hims & Hers inks deal with Eli Lilly to offer branded weight loss drugs
- Barron's — Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement
- hims.ca — Login to your Hims profile
- en.wikipedia.org — Hims & Hers Health - Wikipedia
- hims.ca — Hims - Men's Health & Wellness Online
- app.hims.com — Hims
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community